Shattuck Labs (NASDAQ:STTK) Rating Increased to Hold at Wall Street Zen

Shattuck Labs (NASDAQ:STTK) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts also recently weighed in on the company. Leerink Partners reduced their price target on Shattuck Labs from $4.00 to $2.00 and set an “outperform” rating for the company in a research report on Thursday, August 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a report on Thursday, August 14th. Finally, Wedbush started coverage on Shattuck Labs in a research report on Monday, September 8th. They set an “outperform” rating and a $4.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Shattuck Labs presently has a consensus rating of “Moderate Buy” and an average price target of $4.00.

Shattuck Labs Price Performance

Shares of STTK stock opened at $1.92 on Friday. The stock has a market cap of $91.97 million, a PE ratio of -1.59 and a beta of 1.64. The stock has a 50-day moving average of $1.00 and a 200-day moving average of $1.01. Shattuck Labs has a one year low of $0.69 and a one year high of $3.95.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. As a group, research analysts anticipate that Shattuck Labs will post -1.48 earnings per share for the current year.

Insider Activity at Shattuck Labs

In other news, Director Mona Ashiya acquired 6,306,127 shares of the firm’s stock in a transaction dated Monday, August 25th. The stock was purchased at an average price of $0.87 per share, for a total transaction of $5,486,330.49. Following the completion of the acquisition, the director directly owned 5,255,106 shares in the company, valued at $4,571,942.22. The trade was a -600.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Orbimed Advisors Llc bought 6,306,127 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The shares were bought at an average cost of $0.87 per share, for a total transaction of $5,486,330.49. Following the transaction, the director owned 5,255,106 shares of the company’s stock, valued at $4,571,942.22. The trade was a -600.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.00% of the company’s stock.

Institutional Trading of Shattuck Labs

A number of institutional investors have recently added to or reduced their stakes in STTK. AQR Capital Management LLC increased its stake in Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after acquiring an additional 31,355 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in Shattuck Labs in the 2nd quarter worth approximately $44,000. Nuveen LLC purchased a new stake in Shattuck Labs in the 1st quarter worth approximately $50,000. Bridgeway Capital Management LLC lifted its stake in shares of Shattuck Labs by 147.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock valued at $73,000 after purchasing an additional 55,000 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Shattuck Labs in the 1st quarter valued at approximately $81,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.